Anti-Envelope 1 and 2 Immune Response in Chronic Hepatitis C Patients: Effects of Hepatitis B Virus Co-Infection and Interferon Treatment

Journal of Medical Virology

Volumn 73, Issue 1, 2004, Pages 33-37

  Zampino, Rosa ^a   Marrone, Aldo ^a   Mangoni, Emanuele Durante ^a   Santarpia, Lucio ^a   Sica, Antonello ^a   Tripodi, Marie Francoise ^a   Utili, Riccardo ^a   Ruggiero, Giuseppe ^a   Adinolfi, Luigi Elio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anti E1 E2 antibodies; HBV; HBV DNA; HCV; HCV RNA

Indexed keywords

ALPHA INTERFERON; INTERFERON; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS ENVELOPE GLYCOPROTEIN 1 ANTIBODY; VIRUS ENVELOPE GLYCOPROTEIN 2 ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLEARANCE; DNA DETERMINATION; DRUG EFFECT; DRUG RESPONSE; ELECTROIMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; SEROPREVALENCE; VIRUS CLEARANCE; VIRUS INTERFERENCE; VIRUS REPLICATION;

ADOLESCENT; ADULT; BASE SEQUENCE; CHILD; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 1842561391     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20058     Document Type: Article

References (24)

1. Adinolfi LE, Andreana A, Utili R, Zampino R, Ragone E, Ruggiero G. 1998. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 93:2162-2166.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. 1992. The natural history of community acquired hepatitis C in the United States. N Engl J Med 327:1899-1905.
3. Brunetto MR, Suzuki T, Aizaky H, Flichman D, Colombatto P, Abate ML, Oliveri F, Matsuura Y, Bonino F, Miyamura T. 1996. Variation in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease. Ital J Gastroenterol 28:499-504.
4. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. 1997. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 16:445-451.
5. Depraetere S, Van Kerschaever E, Van Vlierberghe H, Elewaut A, Btouwer JT, Niester HGM, Schalm SW, Maertens G, Leroux-Roels G. 2000. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol 60:126-132.
6. Durante Mangoni E, Forton DM, Ruggiero G, Karayiannis P. 2003. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 70:62-73.
7. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH. 2002. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081-3086.
8. Gane EJ, Maertens G, Ducatteeuw A, Qian KP, Lau JY, Jones H, Davies E, Naoumov NV, Williams R. 1999. Antibodies to hepatitis C virus envelope proteins correlates with hepatitis C viremia after liver transplantation. Transplantation 15:78-84.
9. Harada S, Suzuki R, Ando A, Watanabe Y, Yagi S, Miyamura T, Saito I. 1995. Establishment of a cell line constitutively expression of E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressed protein. J Gen Virol 76:1223-1231.
10. Inoue Y, Suzuki R, Matsuura Y, Harada S, Chiba J, Watanabe Y, Saito I, Miyamura T. 1992. Expression of the amino terminal half of the NS1 region of the hepatitis C virus genome and detection of an antibody to the expressed protein in patients with liver disease. J Gen Virol 73:2151-2154.
11. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T. 1994. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20:1121-1130.
12. Liaw YF. 1995. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 22:1101.
13. Mita E, Hajashi N, Ueda K, Kasahara A, Fusamoto H, Takamizawa A, Matsubara K, Okayama H, Kamada T. 1992. Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type C chronic liver disease. Biochem Biophys Res Commun 183:925-930.
14. Myiamura T, Matsuura Y. 1993. Structural proteins of hepatitis C virus. Trends Microbiol 1:229-231.
15. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
16. Prince AM, Brotman B, Lee DH, Ren H, Moore BS, Scheffel JW. 1999. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infection in chimpanzees and in humans. J Infect Dis 180:987-991.
17. Saracco G, Abate ML, Baldi M, Calvo PL, Manzini P, Brunetto MR, Oliveri F, Kuo G, Chien D, Houghton M. 1994. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. Liver 14:65-70.
18. Scarselli E, Cerino A, Esposito G, Silini E, Mondelli MU, Traboni C. 1995. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp 70) hypervariable region 1 in viremic hepatitis C virus infected patients. J Virol 69:4407-4412.
19. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68:1494-1500.
20. Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T, Munekata E, Muchmore EE, Peterson DA, Mishiro S. 1993. A structurally flexible and antigenically variable N terminal domain of the hepatitis C virus E2/NS1 protein: Implication from an escape from antibodies. Virology 195:297-301.
21. Utili R, Zampino R, Bellopede P, Marracino M, Ragone E, Adinolfi LE, Ruggiero G, Capasso M, Indolfi P, Casale F, Martini A, Di Tullio MT. 1999. Dual or single hepatitis B and C virus infections in childhood cancer survivors: Long term follow up and effect of interferon treatment. Blood 12:4046-4052.
22. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F. 1992. Evidence of immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci USA 89:3468-3472.
23. Yokosuka O, Omata M, Ito Y, Ohto M. 1993. Expression of HCV E2/NS1 protein as a fusion protein with maltose binding protein: Detection of anti-E2/NS1 antibody in chronic liver disease. Gut 34:S64-S65.
24. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Mita E, Ohkawa K, Katayama K, Fusamoto H, Kamada T. 1996. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection. Hepatology 23:947-952.